192 related articles for article (PubMed ID: 29376487)
1. Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa.
Núñez-Navarro NE; Santana FM; Parra LP; Zacconi FC
Curr Med Chem; 2019; 26(17):3175-3200. PubMed ID: 29376487
[TBL] [Abstract][Full Text] [Related]
2. Novel Anthranilamide-Based FXa Inhibitors: Drug Design, Synthesis and Biological Evaluation.
Wang W; Yuan J; Fu X; Meng F; Zhang S; Xu W; Xu Y; Huang C
Molecules; 2016 Apr; 21(4):491. PubMed ID: 27089317
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of serine proteinases from blood coagulation cascade - view on current developments.
Danalev D
Mini Rev Med Chem; 2012 Jul; 12(8):721-30. PubMed ID: 22512557
[TBL] [Abstract][Full Text] [Related]
4. Developments in factor Xa inhibitors for the treatment of thromboembolic disorders.
Lee YK; Player MR
Med Res Rev; 2011 Mar; 31(2):202-83. PubMed ID: 19967784
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
[TBL] [Abstract][Full Text] [Related]
6. Innovative Three-Step Microwave-Promoted Synthesis of
Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibitors of the blood coagulation enzymes.
Kranjc A; Kikelj D
Curr Med Chem; 2004 Oct; 11(19):2535-47. PubMed ID: 15544461
[TBL] [Abstract][Full Text] [Related]
8. Blood coagulation factor Xa as an emerging drug target.
Borensztajn K; Spek CA
Expert Opin Ther Targets; 2011 Mar; 15(3):341-9. PubMed ID: 21250873
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa.
Glauser BF; Rezende RM; Melo FR; Pereira MS; Francischetti IM; Monteiro RQ; Rezaie AR; Mourão PA
Thromb Haemost; 2009 Dec; 102(6):1183-93. PubMed ID: 19967150
[TBL] [Abstract][Full Text] [Related]
10. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide.
Hagemeyer CE; Tomic I; Jaminet P; Weirich U; Bassler N; Schwarz M; Runge MS; Bode C; Peter K
Thromb Haemost; 2004 Jul; 92(1):47-53. PubMed ID: 15213844
[TBL] [Abstract][Full Text] [Related]
11. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
Papadaki S; Tselepis AD
Angiology; 2019 Nov; 70(10):896-907. PubMed ID: 31010298
[TBL] [Abstract][Full Text] [Related]
12. A rapid pro-hemostatic approach to overcome direct oral anticoagulants.
Thalji NK; Ivanciu L; Davidson R; Gimotty PA; Krishnaswamy S; Camire RM
Nat Med; 2016 Aug; 22(8):924-32. PubMed ID: 27455511
[TBL] [Abstract][Full Text] [Related]
13. Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein.
Schuijt TJ; Bakhtiari K; Daffre S; Deponte K; Wielders SJ; Marquart JA; Hovius JW; van der Poll T; Fikrig E; Bunce MW; Camire RM; Nicolaes GA; Meijers JC; van 't Veer C
Circulation; 2013 Jul; 128(3):254-66. PubMed ID: 23817575
[TBL] [Abstract][Full Text] [Related]
14. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
[TBL] [Abstract][Full Text] [Related]
15. New substrate analogue inhibitors of factor Xa containing 4-amidinobenzylamide as P1 residue: part 1.
Schweinitz A; Stürzebecher A; Stürzebecher U; Schuster O; Stürzebecher J; Steinmetzer T
Med Chem; 2006 Jul; 2(4):349-61. PubMed ID: 16848746
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors.
Zhao Y; Jiang M; Zhou S; Wu S; Zhang X; Ma L; Zhang K; Gong P
Eur J Med Chem; 2015; 96():369-80. PubMed ID: 25911624
[TBL] [Abstract][Full Text] [Related]
17. A Structure Based Study of Selective Inhibition of Factor IXa over Factor Xa.
Kundu S; Wu S
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500804
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
19. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
Oliveira DG; Alvarez-Flores MP; Lopes AR; Chudzinski-Tavassi AM
Thromb Haemost; 2012 Sep; 108(3):570-8. PubMed ID: 22782262
[TBL] [Abstract][Full Text] [Related]
20. The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.
Pinto DJ; Qiao JX; Knabb RM
Expert Opin Ther Pat; 2012 Jun; 22(6):645-61. PubMed ID: 22655676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
